Comparison of men with impaired fasting glycaemia to controls and to diabetic subjects with fasting glycaemia from 7.0 to 7.7 mmol/l: Clinical, nutritional and biological status

Diabetes and Metabolism

Volumn 30, Issue 2, 2004, Pages 167-174

  Combe, H ^a   Vol, S ^b   Thevenot A ^a   Lasfargues, G ^a   Caces E ^b   Tichet, J ^b   Lecomte, P ^a,c  

^a CHU BRETONNEAU   (France)

^b Inst Inter Reg pour la S (IRSA)   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

Epidemiology; Impaired fasting glycaemia; Metabolic syndrome; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE;

ABDOMINAL OBESITY; ADULT; AGED; ALCOHOL CONSUMPTION; ANAMNESIS; ARTICLE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; EARLY DIAGNOSIS; FAMILY HISTORY; FAT INTAKE; GLUCOSE BLOOD LEVEL; HEALTH STATUS; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; NUTRITION; OBESITY; QUESTIONNAIRE; RISK FACTOR;

EID: 2642546555     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70103-9     Document Type: Article

References (62)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care, 1998, 21, 1414-31.
2. Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes Care, 1999, 22, 345-54.
3. Grimaldi A, Heurtier A. Epidemiology of cardio-vascular complications of diabetes. Diabetes Metab, 1999, 25, 12-20.
4. Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 1993, 16, 434-44.
5. Harris MI. Impaired glucose tolerance. Prevalence and conversion to NIDDM. Diabet Med, 1996, 13, S9-S11.
6. Göke B. Implications of blood glucose, insulin resistance and β-cell function in impaired glucose tolerance. Diabetes Res Clin Practice, 1998, 40, S15-S20.
7. Jarrett RJ. The cardiovascular risk associated with impaired glucose tolerance. Diabetic Med, 1996, 13, S15-S19.
8. Keen H, Jarrett RJ, McCartney P. The ten-year follow-up of the Bedford survey (1962-72): glucose tolerance and diabetes. Diabetologia, 1982, 22, 73-8.
9. Dowse GK, Zimmet PZ, King H. Relationship between prevalence of impaired glucose tolerance and NIDDM in a population. Diabetes Care, 1991, 14, 968-74.
10. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care, 1997, 20, 537-44.
11. Tuomilheto J, Lindstrom J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med, 2001, 344, 1343-50.
12. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002, 346, 393-403.
13. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet, 2002, 359, 2072-7.
14. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care, 1992, 15, 815-9.
15. The expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 1997, 20, 1183-97.
16. Perry IJ, Wannamethee SG, Whincup PH, Shaper AG. Asymptomatic hyperglycaemia and major ischemic heart disease events in Britain. J Epidemiol Community Health, 1994, 48, 538-42.
17. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study and the Helsinki Policemen Study. Diabetes Care, 1998, 21, 360-7.
18. Meigs JB, Nathan DM, Wilson PW, Cupples LA, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med, 1998, 128,524-33.
19. Bjornholt JV, Erikssen G, Aaser E, et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care, 1999, 22, 45.
20. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care, 1999, 22, 233-40.
21. Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycaemia in the diagnosis and prediction of diabetes. Diabetes Care, 2000, 23, 1108-12.
22. Lim SC, Tai ES, Tan BY, Chew SK, Tan CE. Cardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization provisional report. Diabetes Care, 2000, 23, 278-82.
23. Lecomte P, Vol S, Caces E, et al. Impaired fasting glycaemia and undiagnosed diabetes: prevalence, cardiovascular and behavioural risk factors. Diabetes Metab, 2002, 28, 311-20.
24. Lasfargues G, Vol S, Le Clésiau H, et al. Validité d'un autoquestionnaire court par comparaison avec un entretien diété tique. Presse Med, 1990, 19, 953-7.
25. INSEE. Recensement général de la population française. Imprimerie Nationale. Paris, 1990.
26. Connolly V, Unwin N, Scherriff P, Bilous R, Kelly W. Diabetes prevalence and socioeconomic status: a population based study showing increased prevalence of type 2 diabetes mellitus in deprived areas. J Epidemiol Community Health, 2000, 54, 173-7.
27. Vol S, Doctoriarena A, Le Clésiau H, Tichet J. Comportements alimentaires des adultes en France. Données épidé miologiques. Presse Med, 1992, 21, 1105-9.
28. Oppert JM, Rolland-Cachera MF. Prévalence, évolution dans le temps et conséquences économiques de l'obésité. Med Sciences, 1998, 14, 939-43.
29. Cummings ST, Fraser CG. Variability of capillary plasma glucose in healthy individuals in repeated 75 g oral glucose tolerance tests. Ann Clin Biochem, 1988, 25, 634-7.
30. Harris MI, Eastman RC, Cowie CC, Flegal KM. Comparison of diabetes diagnostic categories in the US population according to 1997 American Diabetes Association and 1980-1985 World Health Organization diagnostic criteria. Diabetes Care, 1997, 20, 1859-62.
31. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in U.S. adults. The third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care, 1998, 21, 518-24.
32. Charles MA, Balkau B, Vauzelle-Kervröedan F, Thibult N, Eschwège E. Revision of diagnostic criteria for diabetes. Lancet, 1996, 348, 1657-8.
33. de Vegt F, Dekker JM, Stehouwer CDA, Nijpels G, Bouter LM, Heine RJ. The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance. Diabetes Care, 1998, 21, 1686-90.
34. Gomez-Perez FJ, Aguilar-Salinas CA, Lopez-Alvarenga JC, Perez-Jauregui J, Guillen-Pineda LE, Rull JA. Lack of agreement between the World Health Organization category of impaired glucose tolerance and the American Diabetes Association category of impaired fasting glucose. Diabetes Care, 1998, 21, 1886-98.
35. The D.E.C.O.D.E. Study Group on behalf on the European Diabetes Epidemiology Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. Br Med J, 1998, 317, 371-5.
36. Burke JP, Williams K, Gaskill SP, Hazuda HP, Haffner SM, Stern MP. Rapid rise in the incidence of type 2 diabetes mellitus from 1987 to 1996. Results from the San Antonio Heart Study. Arch Intern Med, 1999, 159, 1450-6.
37. Hypertension in Diabetes Study (HDS) I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens, 1993, 11, 309-17.
38. Reaven GM, Lithell H, Landsberg L. Hypertension and the associated metabolic abnormalities: the role of insulin-resistance and the sympathoadrenal system. New Engl J Med, 1996, 340, 469-71.
39. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (H.O.T.) randomised trial. HOT study group. Lancet, 1998, 351, 1755-62.
40. Hanley AJ, Karter AJ, Festa A, et al. The Insulin Resistance Atherosclerosis Study. Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study. Diabetes, 2002, 51, 2642-7.
41. Balkau B, Eschwège E, Tichet J, Marre M and the D.E.S.I.R. study group. Proposed criteria for the diagnosis of diabetes: evidence from a French epidemiological study (D.E.S.I.R.). Diabetes Metab, 1997, 23, 428-34.
42. Charles MA, Fontbonne A, Thibult N, Warnet JM. Risk factors for NIDDM in white population. Diabetes, 1991, 40, 796-9.
43. Steiner G. Risk factors for macrovascular disease in type 2 diabetes. Classic lipid abnormalities. Diabetes Care, 1999, 22, C6-C9.
44. Sattar N, Packard CJ, Petrie JR. The end of triglycerides in cardiovascular risk assessment? Rumours of death are greatly exaggerated. Br Med J, 1998, 317, 553-4.
45. Hokanson JE. Hypertriglyceridemia and risk of coronary heart disease. Curr Cardiol Rep, 2002, 4, 488-93.
46. Hudgins LC. Effect of high-carbohydrate feeding on triglyceride and saturated fatty acid synthesis. Proc Soc Exp Biol Med, 2000, 225, 178-83.
47. Dallongeville J, Marecaux N, Ducimetiere P, et al. Influence of alcohol consumption and various beverages on waist girth and waist-to-hip ratio in a sample of French men and women. Int J Obes Relat Metab Disord, 1998, 22, 1178-83.
48. Lemieux I, Almeras N, Mauriege P, et al. Prevalence of hypertriglyceridemic waist' in men who participated in the Quebec Health Survey: association with atherogenic and diabetogenic metabolic risk factors. Can J Cardiol, 2002, 18, 725-32.
49. Bell RA, Mayer-Davis EJ, Martin MA, D'Agostino RB Jr, Haffner SM. Associations between alcohol consumption and insulin sensitivity and cardiovascular disease risk factors: the Insulin Resistance and Atherosclerosis Study. Diabetes Care, 2000, 23, 1630-6.
50. Westerterp-Plantenga MS, Verwegen CR. The appetizing effect of an aperitif in overweight and normal-weight humans. Am J Clin Nutr, 1999, 69, 205-12.
51. Hercberg S, Preziosi P, Galan P, Deheeger M, Dupin H. Apports nutritionnels d'un échantillon représentatif de la population du Valde-Marne. II. Les apports en macronutriments. Rev Epidemiol Santé Publique, 1991, 39, 233-44.
52. Feskens EJ, Virtanen SM, Rasanen L, et al. Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the seven countries study. Diabetes Care, 1995, 18, 1104-12.
53. Salmeron J, Ascherio A, Rimm EB, et al. Dietary fiber, glycemic load and risk of NIDDM in men. Diabetes Care, 1997, 20, 545-50.
54. Schlundt DG, Hill JO, Sbrocco T, Pope Cordle J, Sharp T. The role of breakfast in the treatment of obesity: a randomized clinical trial. Am J Clin Nutr, 1992, 55, 645-51.
55. Gittelsohn J, Wolever TM, Harris SB, Harris-Giraldo R, Hanley AJ, Zinman B. Specific patterns of food consumption and preparation are associated with diabetes and obesity in a native Canadian community. J Nutr, 1998, 128, 541-7.
56. Wang L, Yamaguchi T, Yoshimine T, Katagiri A, Shirogane K, Ohashi Y. A case-control study of risk factors for development of type 2 diabetes: emphasis on physical activity. J Epidemiol, 2002, 12, 424-30.
57. Dyson PA, Hammersley MS, Morris RJ, Holman RR, Turner RC on behalf of the Fasting Hyperglycaemia Group. The fasting hyperglycaemia study: II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose. Metabolism, 1997, 46, 50-5.
58. Polley BA, Jakicic JM, Venditti EM, Barr S, Wing RR. The effects of health beliefs on weight loss in individuals at high risk for NIDDM. Diabetes Care, 1997, 20, 1533-8.
59. Wing RR, Venditti E, Jakicic JM, Polley BA, Lang W. Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care, 1998, 21, 350-9.
60. Engelgau MM, Narayan KMV, Thompson TJ, et al. The cost-effectiveness of screening for type 2 diabetes. JAMA, 1998, 280, 1757-63.
61. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet, 1999, 354, 617-21.
62. Ko GTC, Chan JCN, Yeung VTF, et al. Combined use of a fasting plasma glucose concentration and HbA1c of fructosamine predicts the likelihood of having diabetes in high-risk subjects. Diabetes Care, 1998, 21, 1221-5.